Product Name
ACVR2A, siRNA
Full Product Name
ACVR2A siRNA (Human)
Product Synonym Names
ACVR2; Activin receptor type-2A; Activin receptor type IIA; ACTR-IIA; ACTRIIA
Product Gene Name
ACVR2A sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for P27037
Specificity
ACVR2A siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human ACVR2A gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of ACVR2A sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
ACVR2A sirna
siRNA to inhibit ACVR2A expression using RNA interference
Applications Tested/Suitable for ACVR2A sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for ACVR2A. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001265508.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001278579.1
[Other Products]
UniProt Primary Accession #
P27037
[Other Products]
UniProt Secondary Accession #
Q53TH4; Q6NWV2; Q92474; B2RAB8; B4DWQ2; D3DP85[Other Products]
UniProt Related Accession #
P27037[Other Products]
Molecular Weight
45,713 Da
NCBI Official Full Name
activin receptor type-2A isoform 1
NCBI Official Synonym Full Names
activin A receptor, type IIA
NCBI Official Symbol
ACVR2A [Similar Products]
NCBI Official Synonym Symbols
ACVR2; ACTRII
[Similar Products]
NCBI Protein Information
activin receptor type-2A
UniProt Protein Name
Activin receptor type-2A
UniProt Synonym Protein Names
Activin receptor type IIA; ACTR-IIA; ACTRIIA
Protein Family
Activin receptor
UniProt Gene Name
ACVR2A [Similar Products]
UniProt Synonym Gene Names
ACVR2; ACTR-IIA; ACTRIIA [Similar Products]
UniProt Entry Name
AVR2A_HUMAN
NCBI Summary for ACVR2A
This gene encodes a receptor that mediates the functions of activins, which are members of the transforming growth factor-beta (TGF-beta) superfamily involved in diverse
biological processes. The encoded protein is a transmembrane serine-threonine kinase receptor which mediates signaling by forming heterodimeric complexes with various combinations of type I and type II receptors and ligands in a cell-specific manner. The encoded type II receptor is primarily involved in ligand-binding and includes an extracellular ligand-binding domain, a transmembrane domain and a cytoplasmic serine-threonine kinase domain. This gene may be associated with susceptibility to preeclampsia, a pregnancy-related disease which can result in maternal and fetal morbidity and mortality. Alternative splicing results in multiple transcript variants of this gene. [provided by RefSeq, Jun 2013]
UniProt Comments for ACVR2A
ACVR2A: a tyrosine-kinase like receptor kinase of the STKR family. The holoreceptor receptor is a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. Each is composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic kinase domain. Type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. Type II receptor kinases are apparently constitutively active.
Protein type: Protein kinase, Ser/Thr (receptor); Protein kinase, TKL; Membrane protein, integral; Motility/polarity/chemotaxis; Kinase, protein; EC 2.7.11.30; TKL group; STKR family; Type2 subfamily
Chromosomal Location of Human Ortholog: 2q22.3
Cellular Component: cell surface; integral to plasma membrane; cytoplasm; plasma membrane; receptor complex
Molecular Function: activin receptor activity; protein self-association; metal ion binding; transmembrane receptor protein serine/threonine kinase activity; PDZ domain binding; transforming growth factor beta receptor activity; protein serine/threonine kinase activity; protein binding; growth factor binding; activin binding; coreceptor activity; ATP binding; receptor signaling protein serine/threonine kinase activity
Biological Process: embryonic skeletal development; positive regulation of erythrocyte differentiation; regulation of BMP signaling pathway; activin receptor signaling pathway; Sertoli cell proliferation; gastrulation with mouth forming second; positive regulation of bone mineralization; protein amino acid phosphorylation; BMP signaling pathway; anterior/posterior pattern formation; positive regulation of osteoblast differentiation; positive regulation of activin receptor signaling pathway; transmembrane receptor protein serine/threonine kinase signaling pathway; spermatogenesis; mesoderm development; regulation of nitric-oxide synthase activity; positive regulation of protein amino acid phosphorylation; sperm ejaculation; determination of left/right symmetry; penile erection
Research Articles on ACVR2A
1. For ACVR2A SNPs (rs10497025, rs1128919, rs13430086), no statistically significant difference was found between preeclampsia and control groups in terms of genotype and allele frequencies.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
